奥比中光：10月24日召开董事会会议

Group 1 - The core point of the article is that Aobo Zhongguang (SH 688322) held its 20th meeting of the second board of directors on October 24, 2025, to discuss the conditions for the second vesting period of the 2022 restricted stock incentive plan [1] - For the year 2024, Aobo Zhongguang's revenue composition is as follows: AIoT accounts for 52.82%, biometric recognition accounts for 40.93%, industrial 3D measurement accounts for 4.69%, and other businesses account for 1.56% [1] - As of the time of reporting, Aobo Zhongguang has a market capitalization of 34.4 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year, indicating a hot secondary market for biomedicine [1] - There is a discussion on why fundraising in the primary market is facing challenges despite the active secondary market, as highlighted by the conversation with Lu Gang, a partner at Chuangdong Investment [1]